Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 18 | 2025 | 598 | 4.960 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2024 | 1098 | 1.420 |
Why?
|
| Mohs Surgery | 6 | 2024 | 24 | 1.370 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2024 | 63 | 1.350 |
Why?
|
| Dermatology | 5 | 2022 | 40 | 1.090 |
Why?
|
| Dermatologic Surgical Procedures | 2 | 2017 | 16 | 1.050 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2021 | 50 | 1.050 |
Why?
|
| Neuromuscular Agents | 3 | 2021 | 27 | 0.970 |
Why?
|
| Skin | 6 | 2022 | 589 | 0.890 |
Why?
|
| Melanoma | 2 | 2024 | 471 | 0.780 |
Why?
|
| Dermatitis Herpetiformis | 2 | 2011 | 9 | 0.760 |
Why?
|
| Tissue Embedding | 1 | 2020 | 6 | 0.730 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2020 | 25 | 0.720 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 99 | 0.670 |
Why?
|
| Laser Therapy | 3 | 2017 | 148 | 0.660 |
Why?
|
| Cosmetic Techniques | 3 | 2021 | 29 | 0.640 |
Why?
|
| beta Catenin | 1 | 2020 | 267 | 0.630 |
Why?
|
| Chemexfoliation | 1 | 2017 | 3 | 0.590 |
Why?
|
| Dermabrasion | 1 | 2017 | 3 | 0.590 |
Why?
|
| Isotretinoin | 1 | 2017 | 21 | 0.590 |
Why?
|
| Carcinoma in Situ | 1 | 2018 | 52 | 0.590 |
Why?
|
| Regenerative Medicine | 1 | 2017 | 25 | 0.560 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 538 | 0.560 |
Why?
|
| Immunotherapy | 1 | 2022 | 698 | 0.550 |
Why?
|
| Dermatologic Agents | 1 | 2017 | 73 | 0.550 |
Why?
|
| Humans | 45 | 2025 | 89970 | 0.500 |
Why?
|
| Patient Safety | 1 | 2017 | 219 | 0.480 |
Why?
|
| Dapsone | 2 | 2011 | 10 | 0.480 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 5 | 0.480 |
Why?
|
| Cellulitis | 1 | 2014 | 19 | 0.480 |
Why?
|
| Stem Cells | 1 | 2017 | 376 | 0.470 |
Why?
|
| Videotape Recording | 1 | 2014 | 48 | 0.460 |
Why?
|
| Internship and Residency | 3 | 2022 | 1062 | 0.450 |
Why?
|
| Psoriasis | 2 | 2014 | 245 | 0.440 |
Why?
|
| Biopsy | 4 | 2024 | 1184 | 0.400 |
Why?
|
| Botulinum Toxins | 1 | 2021 | 17 | 0.390 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2011 | 5 | 0.380 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2011 | 9 | 0.380 |
Why?
|
| Panniculitis | 1 | 2011 | 10 | 0.370 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2011 | 16 | 0.370 |
Why?
|
| Hair | 2 | 2010 | 56 | 0.360 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1744 | 0.360 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2010 | 5 | 0.360 |
Why?
|
| Hypothermia, Induced | 1 | 2011 | 82 | 0.350 |
Why?
|
| Dermatitis | 1 | 2010 | 34 | 0.340 |
Why?
|
| Malnutrition | 1 | 2010 | 33 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1055 | 0.310 |
Why?
|
| Clinical Competence | 1 | 2014 | 796 | 0.310 |
Why?
|
| Consensus | 2 | 2024 | 366 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 952 | 0.300 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 435 | 0.290 |
Why?
|
| Prospective Studies | 7 | 2024 | 4331 | 0.270 |
Why?
|
| Keratinocytes | 3 | 2006 | 146 | 0.260 |
Why?
|
| Dermatofibrosarcoma | 1 | 2025 | 14 | 0.240 |
Why?
|
| Neurotoxins | 2 | 2015 | 49 | 0.230 |
Why?
|
| Male | 16 | 2024 | 42682 | 0.230 |
Why?
|
| Delphi Technique | 1 | 2024 | 101 | 0.230 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2024 | 17 | 0.220 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2003 | 6 | 0.220 |
Why?
|
| Female | 16 | 2024 | 46595 | 0.210 |
Why?
|
| Skin Diseases | 2 | 2017 | 174 | 0.210 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2331 | 0.210 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6783 | 0.200 |
Why?
|
| Methylation | 1 | 2023 | 269 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 569 | 0.200 |
Why?
|
| Paget Disease, Extramammary | 1 | 2022 | 10 | 0.200 |
Why?
|
| Prognosis | 3 | 2022 | 3798 | 0.200 |
Why?
|
| Middle Aged | 12 | 2024 | 26148 | 0.190 |
Why?
|
| Rubber | 1 | 2020 | 6 | 0.180 |
Why?
|
| Adhesives | 1 | 2020 | 5 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2024 | 8273 | 0.180 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1801 | 0.180 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 280 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2022 | 584 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2023 | 2887 | 0.170 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2019 | 2 | 0.170 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2019 | 7 | 0.170 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2019 | 7 | 0.170 |
Why?
|
| Papilloma | 1 | 2019 | 22 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2003 | 469 | 0.160 |
Why?
|
| RNA | 1 | 2023 | 583 | 0.160 |
Why?
|
| Aged | 11 | 2024 | 19254 | 0.160 |
Why?
|
| Immunocompetence | 1 | 2018 | 26 | 0.150 |
Why?
|
| Lipectomy | 1 | 2017 | 9 | 0.150 |
Why?
|
| Physical Examination | 2 | 2024 | 149 | 0.140 |
Why?
|
| Platelet-Rich Plasma | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cicatrix | 1 | 2017 | 68 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 142 | 0.140 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1607 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2025 | 1704 | 0.130 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 182 | 0.130 |
Why?
|
| Adipocytes | 1 | 2017 | 163 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2015 | 3680 | 0.130 |
Why?
|
| Injections | 2 | 2021 | 116 | 0.120 |
Why?
|
| Preservation, Biological | 1 | 2015 | 4 | 0.120 |
Why?
|
| Drug Storage | 1 | 2015 | 4 | 0.120 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2015 | 19 | 0.120 |
Why?
|
| Darier Disease | 1 | 2015 | 4 | 0.120 |
Why?
|
| Drug Contamination | 1 | 2015 | 12 | 0.120 |
Why?
|
| Eyebrows | 1 | 2015 | 10 | 0.120 |
Why?
|
| Tissue Engineering | 1 | 2017 | 191 | 0.120 |
Why?
|
| Ear, External | 1 | 2015 | 26 | 0.120 |
Why?
|
| Lasers, Solid-State | 1 | 2015 | 8 | 0.120 |
Why?
|
| Low-Level Light Therapy | 1 | 2015 | 15 | 0.120 |
Why?
|
| Chickenpox | 1 | 2015 | 38 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 28 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 778 | 0.120 |
Why?
|
| Exanthema | 1 | 2015 | 40 | 0.120 |
Why?
|
| Standard of Care | 1 | 2015 | 65 | 0.120 |
Why?
|
| Viscosupplements | 1 | 2013 | 5 | 0.110 |
Why?
|
| Fibroblasts | 1 | 2017 | 759 | 0.110 |
Why?
|
| Forehead | 1 | 2013 | 15 | 0.110 |
Why?
|
| Cetuximab | 1 | 2014 | 115 | 0.110 |
Why?
|
| Leg | 1 | 2014 | 140 | 0.110 |
Why?
|
| Skin Aging | 1 | 2013 | 30 | 0.110 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 51 | 0.110 |
Why?
|
| Vacuum Curettage | 1 | 2013 | 5 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 234 | 0.110 |
Why?
|
| Hyperhidrosis | 1 | 2013 | 10 | 0.110 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 116 | 0.110 |
Why?
|
| Operating Rooms | 1 | 2014 | 125 | 0.110 |
Why?
|
| Neutrophils | 1 | 2014 | 311 | 0.110 |
Why?
|
| Microinjections | 1 | 2012 | 71 | 0.100 |
Why?
|
| Needles | 1 | 2012 | 40 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 202 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 1145 | 0.090 |
Why?
|
| Serologic Tests | 1 | 2011 | 43 | 0.090 |
Why?
|
| Immunoglobulin A | 1 | 2011 | 83 | 0.090 |
Why?
|
| Neurotransmitter Agents | 1 | 2021 | 108 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 231 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 178 | 0.090 |
Why?
|
| Diet, Gluten-Free | 1 | 2011 | 58 | 0.090 |
Why?
|
| Face | 1 | 2021 | 118 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 91 | 0.090 |
Why?
|
| Microscopy | 1 | 2010 | 87 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 865 | 0.080 |
Why?
|
| Adult | 7 | 2024 | 26822 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 469 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 2011 | 243 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 261 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 1862 | 0.080 |
Why?
|
| Transcription Factor AP-2 | 2 | 2006 | 14 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2011 | 284 | 0.080 |
Why?
|
| Time Factors | 2 | 2015 | 5359 | 0.080 |
Why?
|
| Celiac Disease | 1 | 2011 | 214 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2767 | 0.070 |
Why?
|
| Comorbidity | 1 | 2011 | 953 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1929 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2018 | 9210 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2499 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2024 | 50 | 0.060 |
Why?
|
| Uncertainty | 1 | 2024 | 76 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2015 | 151 | 0.060 |
Why?
|
| Skin Pigmentation | 1 | 2024 | 32 | 0.060 |
Why?
|
| Phenotype | 1 | 2010 | 2458 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 42 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 54 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2010 | 3773 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2006 | 499 | 0.050 |
Why?
|
| Private Practice | 1 | 2022 | 11 | 0.050 |
Why?
|
| Equipment Design | 2 | 2015 | 422 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 2363 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 281 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2022 | 73 | 0.050 |
Why?
|
| Animals | 5 | 2011 | 27528 | 0.050 |
Why?
|
| Patient Care | 1 | 2022 | 102 | 0.050 |
Why?
|
| Young Adult | 4 | 2015 | 6410 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 692 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2025 | 384 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2003 | 443 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2003 | 1244 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 122 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2002 | 284 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2003 | 1533 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1134 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1352 | 0.040 |
Why?
|
| Deoxycholic Acid | 1 | 2017 | 10 | 0.040 |
Why?
|
| Mesotherapy | 1 | 2017 | 2 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 573 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2017 | 30 | 0.040 |
Why?
|
| Photography | 1 | 2017 | 37 | 0.040 |
Why?
|
| Ultrasonic Therapy | 1 | 2017 | 37 | 0.040 |
Why?
|
| Mice | 4 | 2006 | 11851 | 0.040 |
Why?
|
| United States | 2 | 2024 | 7108 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2006 | 3404 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2655 | 0.030 |
Why?
|
| Keratins | 2 | 2006 | 63 | 0.030 |
Why?
|
| Gloves, Surgical | 1 | 2013 | 6 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2013 | 19 | 0.030 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 24 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 47 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 476 | 0.030 |
Why?
|
| Universities | 1 | 2013 | 146 | 0.030 |
Why?
|
| Axilla | 1 | 2013 | 103 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 53 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2012 | 59 | 0.030 |
Why?
|
| Urban Population | 1 | 2013 | 225 | 0.030 |
Why?
|
| Technology, Pharmaceutical | 1 | 2012 | 33 | 0.020 |
Why?
|
| Wound Healing | 1 | 2013 | 361 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 111 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 92 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2006 | 961 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 9342 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1603 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2013 | 432 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2006 | 1576 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 1714 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 798 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2006 | 8 | 0.020 |
Why?
|
| Chromones | 1 | 2006 | 31 | 0.020 |
Why?
|
| Skin Abnormalities | 1 | 2006 | 11 | 0.020 |
Why?
|
| Hair Diseases | 1 | 2006 | 9 | 0.020 |
Why?
|
| Dermis | 1 | 2006 | 28 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2006 | 50 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 67 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2006 | 137 | 0.020 |
Why?
|
| Integrases | 1 | 2006 | 63 | 0.020 |
Why?
|
| Morpholines | 1 | 2006 | 70 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2006 | 162 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 117 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 137 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 155 | 0.020 |
Why?
|
| Epidermis | 1 | 2006 | 102 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 1983 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 223 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 198 | 0.020 |
Why?
|
| Quinazolines | 1 | 2006 | 212 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 524 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 341 | 0.010 |
Why?
|
| GATA3 Transcription Factor | 1 | 2003 | 48 | 0.010 |
Why?
|
| Hair Follicle | 1 | 2003 | 29 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 1130 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3475 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 644 | 0.010 |
Why?
|
| Sp2 Transcription Factor | 1 | 2002 | 1 | 0.010 |
Why?
|
| Keratin-5 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Keratin-15 | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2002 | 22 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 2002 | 28 | 0.010 |
Why?
|
| Sebaceous Glands | 1 | 2002 | 28 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2002 | 173 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2003 | 184 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1309 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 1179 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 1311 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1669 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 1121 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 2329 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3024 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1158 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 2887 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2002 | 1665 | 0.010 |
Why?
|